Opportunity overview
Project title: NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives commencing 1st April 2026 Offer reference number: CM/TNS/25/5737 Period of framework: 1 April 2026 to 31 March 2028 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Awarded to
Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.
Abbvie Ltd
- Shared contract value
- £160m
- Awarded
- Not supplied
- Contract signed
- 11 Mar 2026
- Including VAT
- £192m
- Suppliers
- One of 2 awarded suppliers
- Award ID
- 1
- Status
- active
- Identifier
- GB-PPON PHRQ-1133-WGCH
- Location
- Maidenhead, UKJ11, SL6 4UB, United Kingdom
Gilead Sciences Limited
- Shared contract value
- £160m
- Awarded
- Not supplied
- Contract signed
- 11 Mar 2026
- Including VAT
- £192m
- Suppliers
- One of 2 awarded suppliers
- Award ID
- 1
- Status
- active
- Identifier
- GB-PPON PPDW-8775-RCQV
- Location
- London, UKI31, WC1V 7EE, United Kingdom
Classification
No classification was supplied.
Lots
- Lot 1Value not stated
Documents and notices
- Contract details notice on Find a TenderOpen source ↗
- contractSignedOpen source ↗
- contractSignedOpen source ↗